The efflux pump inhibitor timcodar improves the potency of antimycobacterial agents

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 3, 2015, Pages 1534-1541

  Grossman, Trudy H ^a,c   Shoen, Carolyn M ^b   Jones, Steven M ^a   Jones, Peter L ^a,d   Cynamon, Michael H ^b   Locher, Christopher P ^a,e  

^a VERTEX PHARMACEUTICALS   (United States)

^b Central New York Research Corporation   (United States)

^c Tetraphase Pharmaceuticals   (United States)

^d Driftwood Kayak   (United States)

^e Karaden Farms   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMYCOBACTERIAL AGENT; BEDAQUILINE; CLOFAZIMINE; ISONIAZID; MOXIFLOXACIN; RIFAMPICIN; TIMCODAR; PYRIDINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENCY; DRUG POTENTIATION; FEMALE; GROWTH INHIBITION; HOST PATHOGEN INTERACTION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; LUNG; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PLASMA; PRIORITY JOURNAL; RELAPSE; ANIMAL; C57BL MOUSE; CELL LINE; DRUG EFFECTS; IMMUNOLOGY; MACROPHAGE; MICROBIAL SENSITIVITY TEST;

ANIMALS; ANTITUBERCULAR AGENTS; CELL LINE; DRUG SYNERGISM; FEMALE; HUMANS; MACROPHAGES; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PYRIDINES;

EID: 84923242858     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04271-14     Document Type: Article

References (45)

1. WHO. 2013. Global tuberculosis report 2013. WHO, Geneva, Switzerland.
2. Martin SK, Oduola AM, Milhous WK. 1987. Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science 235:899-901. http://dx.doi.org/10.1126/science.3544220.
3. Van Bambeke F, Pages JM, Lee VJ. 2006. Inhibitors of bacterial efflux pumps as adjuvants in antibiotic treatments and diagnostic tools for detection of resistance by efflux. Recent Pat Antiinfect Drug Discov 1:157-175. http://dx.doi.org/10.2174/157489106777452692.
4. Li X-Z, Nikaido H. 2004. Efflux-mediated drug resistance in bacteria. Drugs 64:159-204. http://dx.doi.org/10.2165/00003495-200464020-00004.
5. Nobili S, Landini I, Giglioni B, Mini E. 2006. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 7:861-879. http://dx.doi.org/10.2174/138945006777709593.
6. De Rossi E, Ainsa JA, Riccardi G. 2006. Role of mycobacterial efflux transporters in drug resistance: an unresolved question. FEMS Microbiol Rev 30:36-52. http://dx.doi.org/10.1111/j.1574-6976.2005.00002.x.
7. Louw GE, Warren RM, Gey van Pittius NC, McEvoy CR, Van Helden PD, Victor TC. 2009. A balancing act: efflux/influx in mycobacterial drug resistance. Antimicrob Agents Chemother 53:3181-3189. http://dx.doi.org/10.1128/AAC.01577-08.
8. Viveiros M, Leandro C, Amaral L. 2003. Mycobacterial efflux pumps and chemotherapeutic implications. Int J Antimicrob Agents 22:274-278. http://dx.doi.org/10.1016/S0924-8579(03)00208-5.
9. Adams KN, Szumowski JD, Ramakrishnan L. 2014. Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs. J Infect Dis 210:456-466. http://dx.doi.org/10.1093/infdis/jiu095.
10. Adams KN, Takaki K, Connolly LE, Wiedenhoft H, Winglee K, Humbert O, Edelstein PH, Cosma CL, Ramakrishnan L. 2011. Drug tolerance in replicating mycobacteria mediated by a macrophageinduced efflux mechanism. Cell 145:39-53. http://dx.doi.org/10.1016/j.cell.2011.02.022.
11. Sharma S, Kumar M, Sharma S, Nargotra A, Koul S, Khan IA. 2010. Piperine as an inhibitor of Rv1258c, a putative multidrug efflux pump of Mycobacterium tuberculosis. J Antimicrob Chemother 65:1694-1701. http://dx.doi.org/10.1093/jac/dkq186.
12. Gupta S, Tyagi S, Almeida DV, Maiga MC, Ammerman NC, Bishai WR. 2013. Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor. Am J Res Crit Care Med 188:600-607. http://dx.doi.org/10.1164/rccm.201304-0650OC.
13. Balganesh M, Dinesh N, Sharma S, Kuruppath S, Nair AV, Sharma U. 2012. Efflux pumps of Mycobacterium tuberculosis play a significant role in antituberculosis activity of potential drug candidates. Antimicrob Agents Chemother 56:2643-2651. http://dx.doi.org/10.1128/AAC.06003-11.
14. Rodrigues L, Villellas C, Bailo R, Viveiros M, Ainsa JA. 2013. Role of the Mmr efflux pump in drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 57:751-757. http://dx.doi.org/10.1128/AAC.01482-12.
15. Mullin S, Mani N, Grossman TH. 2004. Inhibition of antibiotic efflux in bacteria by the novel multidrug resistance inhibitors biricodar (VX-710) and timcodar (VX-853). Antimicrob Agents Chemother 48:4171-4176. http://dx.doi.org/10.1128/AAC.48.11.4171-4176.2004.
16. Pucci MJ, Ackerman M, Thanassi JA, Shoen CM, Cynamon MH. 2010. In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates. Antimicrob Agents Chemother 54:3478-3480. http://dx.doi.org/10.1128/AAC.00287-10.
17. Franzblau SG, Witzig RS, McLaughlin JC, Torres P, Madico G, Hernandez A, Degnan MT, Cook MB, Quenzer VK, Ferguson RM, Gilman RH. 1998. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate alamarBlue assay. J Clin Microbiol 36:362-366.
18. Andreu N, Fletcher T, Krishnan N, Wiles S, Robertson BD. 2012. Rapid measurement of antituberculosis drug activity in vitro and in macrophages using bioluminescence. J Antimicrob Chemother 67:404-414. http://dx.doi.org/10.1093/jac/dkr472.
19. Murray JL, Mehta K, Lopez-Berestein G. 1988. Induction of adenosine deaminase and 5= nucleotidase activity in cultured human blood monocytes and monocytic leukemia (THP-1) cells by differentiating agents. J Leukoc Biol 44:205-211.
20. Heifets LB. 1996. Clinical mycobacteriology. Drug susceptibility testing. Clin Lab Med 16:641-656.
21. Chou TC. 2006. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58:621-681. http://dx.doi.org/10.1124/pr.58.3.10.
22. Crowle AJ, Elkins N, May MH. 1988. Effectiveness of ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium, and rifampin against M. tuberculosis in cultured human macrophages. Am Rev Respir Dis 137:1141-1146. http://dx.doi.org/10.1164/ajrccm/137.5.1141.
23. Keller C, Lauber J, Blumenthal A, Buer J, Ehlers S. 2004. Resistance and susceptibility to tuberculosis analysed at the transcriptome level: lessons from mouse macrophages. Tuberculosis (Edinb) 84:144-158. http://dx.doi.org/10.1016/j.tube.2003.12.003.
24. Brillault J, De Castro WV, Harnois T, Kitzis A, Olivier JC, Couet W. 2009. P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model. Antimicrob Agents Chemother 53:1457-1462. http://dx.doi.org/10.1128/AAC.01253-08.
25. Germann UA, Ford PJ, Shlyakhter D, Mason VS, Harding MW. 1997. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs 8:141-155. http://dx.doi.org/10.1097/00001813-199702000-00005.
26. Germann UA, Harding MW. 1995. Chemosensitizers to overcome and prevent multidrug resistance? J Natl Cancer Inst 87:1573-1575. http://dx.doi.org/10.1093/jnci/87.21.1573.
27. Hodge G, Holmes M, Jersmann H, Reynolds PN, Hodge S. 2013. The drug efflux pump Pgp1 in pro-inflammatory lymphocytes is a target for novel treatment strategies in COPD. Respir Res 14:63. http://dx.doi.org/10.1186/1465-9921-14-63.
28. Michot JM, Seral C, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. 2005. Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages. Antimicrob Agents Chemother 49:2429-2437. http://dx.doi.org/10.1128/AAC.49.6.2429-2437.2005.
29. Amaral L, Martins M, Viveiros M. 2007. Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J Antimicrob Chemother 59:1237-1246. http://dx.doi.org/10.1093/jac/dkl500.
30. Singh M, Jadaun GP, Ramdas , Srivastava K, Chauhan V, Mishra R, Gupta K, Nair S, Chauhan DS, Sharma VD, Venkatesan K, Katoch VM. 2011. Effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates. Indian J Med Res 133:535-540.
31. Germann UA, Shlyakhter D, Mason VS, Zelle RE, Duffy JP, Galullo V, Armistead DM, Saunders JO, Boger J, Harding MW. 1997. Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs 8:125-140. http://dx.doi.org/10.1097/00001813-199702000-00004.
32. Mitchell AM, Tom M, Mortimer RH. 2005. Thyroid hormone export from cells: contribution of P-glycoprotein. J Endocrinol 185:93-98. http://dx.doi.org/10.1677/joe.1.06096.
33. Dobson PD, Kell DB. 2008. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat Rev Drug Discov 7:205-220. http://dx.doi.org/10.1038/nrd2438.
34. Van Bambeke F, Michot JM, Tulkens PM. 2003. Antibiotic efflux pumps in eukaryotic cells: occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodynamics. J Antimicrob Chemother 51:1067-1077. http://dx.doi.org/10.1093/jac/dkg225.
35. Dartois V, Barry CE, III. 2013. A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. Bioorg Med Chem Lett 23:4741-4750. http://dx.doi.org/10.1016/j.bmcl.2013.07.006.
36. Davis SL, Nuermberger EL, Um PK, Vidal C, Jedynak B, Pomper MG, Bishai WR, Jain SK. 2009. Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother 53:4879-4884. http://dx.doi.org/10.1128/AAC.00789-09.
37. Kjellsson MC, Via LE, Goh A, Weiner D, Low KM, Kern S, Pillai G, Barry CE, III, Dartois V. 2012. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob Agents Chemother 56:446-457. http://dx.doi.org/10.1128/AAC.05208-11.
38. Bigi F, Gioffre A, Klepp L, Santangelo MP, Alito A, Caimi K, Meikle V, Zumarraga M, Taboga O, Romano MI, Cataldi A. 2004. The knockout of the lprG-Rv1410 operon produces strong attenuation of Mycobacterium tuberculosis. Microbes Infect 6:182-187. http://dx.doi.org/10.1016/j.micinf.2003.10.010.
39. Domenech P, Reed MB, Barry CE, III. 2005. Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance. Infect Immun 73:3492-3501. http://dx.doi.org/10.1128/IAI.73.6.3492-3501.2005.
40. Farrow MF, Rubin EJ. 2008. Function of a mycobacterial major facilitator superfamily pump requires a membrane-associated lipoprotein. J Bacteriol 190:1783-1791. http://dx.doi.org/10.1128/JB.01046-07.
41. Calgin MK, Sahin F, Turegun B, Gerceker D, Atasever M, Koksal D, Karasartova D, Kiyan M. 2013. Expression analysis of efflux pump genes among drug-susceptible and multidrug-resistant Mycobacterium tuberculosis clinical isolates and reference strains. Diagn Microbiol Infect Dis 76:291-297. http://dx.doi.org/10.1016/j.diagmicrobio.2013.02.033.
42. Chatterjee A, Saranath D, Bhatter P, Mistry N. 2013. Global transcriptional profiling of longitudinal clinical isolates of Mycobacterium tuberculosis exhibiting rapid accumulation of drug resistance. PLoS One 8:e54717. http://dx.doi.org/10.1371/journal.pone.0054717.
43. Sheen P, Lozano K, Gilman RH, Valencia HJ, Loli S, Fuentes P, Grandjean L, Zimic M. 2013. pncA gene expression and prediction factors on pyrazinamide resistance in Mycobacterium tuberculosis. Tuberculosis (Edinb) 93:515-522. http://dx.doi.org/10.1016/j.tube.2013.03.005.
44. Zimic M, Fuentes P, Gilman RH, Gutierrez AH, Kirwan D, Sheen P. 2012. Pyrazinoic acid efflux rate in Mycobacterium tuberculosis is a better proxy of pyrazinamide resistance. Tuberculosis (Edinb) 92:84-91. http://dx.doi.org/10.1016/j.tube.2011.09.002.
45. Eldholm V, Norheim G, von der Lippe B, Kinander W, Dahle UR, Caugant DA, Mannsaker T, Mengshoel AT, Dyrrol-Rilse AM, Balloux F. 2014. Evolution of extensively drug-resistant Mycobacterium tuberculosis from a susceptible ancestor in a single patient. Genome Biol 15:490. http://dx.doi.org/10.1186/s13059-014-0490-3.